Changes in Breast Cancer Optoacoustic Imaging Features During Neoadjuvant Therapy and Correlation with Pathologic Response: A Feasibility Study
Journal of Breast Imaging · 06.11.2026
DOI: 10.1093/jbi/wbag049 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Breast Imaging, online erschienen am 06.11.2026. Verfasst von Basak E Dogan und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Department of Radiology, Dallas, TX, USA. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Seno Medical Instruments, Inc.
Abstract (Originalsprache)
Objective
To assess whether changes in optoacoustic/ultrasound (OA/US) imaging features during neoadjuvant chemotherapy (NAC) correlate with treatment response, compared to US-derived tumor volumetric changes.
Methods
In this IRB-approved, HIPAA-compliant prospective study, 20 patients with cT1–T4, cN1–3 breast cancer underwent serial OA/US imaging at baseline, post-cycle 1, mid-therapy, and presurgery. Optoacoustic/US features, including internal vessels (OAint), internal hemoglobin (OAHb), deoxyHb, peripheral zone (OApz), and boundary zone (OAbz) were assessed using a validated scoring system. US tumor volume and OA/US changes were compared to residual cancer burden (RCB) and pathologic complete response (pCR). Responders were defined as RCB 0–II; non-responders were defined as RCB III. Comparisons were made using Wilcoxon Rank-Sum tests and univariate logistic regression.
Results
Mean age was 50.4 years (SD ± 9.5). Mean tumor size was 26.3 mm (SD ± 9.7). Pathology showed pCR in 6 (30%), partial response in 11 (55%), and no response in 3 (15%), with mean overall residual tumor cellularity of 32.7% (SD ± 33.5). Regression analysis showed no significant correlation between percent volume change and pCR at cycle1 or mid-therapy. Patients achieving pCR had significantly lower residual OAHb after cycle 1 (76.4% vs 108.8%, P = 0.01). At preoperative, all OA/US features decreased significantly more in pCR vs non-pCR cases (all P < 0.05). Higher individual and total OA/US scores at cycle 1 reflecting elevated hemoglobin and lower relative oxygen saturation predicted RCB III status. The RCB III tumors had significantly higher mean residual deoxygenated blush score at cycle 1 (117.8% vs 64.8%, P = 0.03).
Conclusion
Optoacoustic/US feature changes were more highly correlated with pCR than US volumetric decrease and show promise as a potential tool to non-invasively identify pCR. Early cycle 1 OA/US scores may help identify poor responders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Texas Southwestern Medical Center, Department of Radiology, Dallas, TX, USA.
- University of Texas Southwestern Medical Center, Department of Internal Medicine, Breast Medical Oncology, Dallas, TX, USA.
- University of Texas Southwestern Medical Center, Department of Pathology, Dallas, TX, USA.
- Department of Radiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
ORCID-Profile: Basak E Dogan, B Bersu Ozcan
Förderung
- Seno Medical Instruments, Inc
Zitieren
APA
Dogan, B. E., Ozcan, B. B., Seiler, S. J., McArthur, H., Peng, Y., & Stavros, A. T. (2026). Changes in Breast Cancer Optoacoustic Imaging Features During Neoadjuvant Therapy and Correlation with Pathologic Response: A Feasibility Study. Journal of Breast Imaging. https://doi.org/10.1093/jbi/wbag049
Vancouver
Dogan BE, Ozcan BB, Seiler SJ, McArthur H, Peng Y, Stavros AT. Changes in Breast Cancer Optoacoustic Imaging Features During Neoadjuvant Therapy and Correlation with Pathologic Response: A Feasibility Study. Journal of Breast Imaging. 2026. doi:10.1093/jbi/wbag049
BibTeX
@article{Dogan2026,
author = {Dogan, Basak E and Ozcan, B Bersu and Seiler, Stephen J and McArthur, Heather and Peng, Yan and Stavros, A Thomas},
title = {Changes in Breast Cancer Optoacoustic Imaging Features During Neoadjuvant Therapy and Correlation with Pathologic Response: A Feasibility Study},
journal = {Journal of Breast Imaging},
year = {2026},
doi = {10.1093/jbi/wbag049}
}
EUVIMED